2022-06-23 | OTCQB:PVCT | Press release
KNOXVILLE, TN, June 23, 2022 (GLOBE NEWSWIRE) — Provectus (OTCQB: PVCT) today announced that the company’s shareholders have approved the proposals of Provectus’ Board of Directors (Board) to seek authorization to proceed with a reverse stock split and authorized share reduction.
At the company’s 2022 annual meeting of shareholders held in Knoxville, Tennessee, on June 22, shareholders also approved recommendations from the board of directors regarding director election proposals, approval of compensation for Provectus’ senior management appointments and ratification of the company’s registered independent public accounting firm.
A copy of Provectus’ Form 8-K filed on June 23 that provided shareholder voting details on the five board proposals, including a brief description and vote tabulation for each proposal, can be found here : https://www.sec.gov/ix?doc=/Archives/edgar/data/315545/000149315222017562/form8-k.htm.
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company that develops immunotherapy drugs for different disease areas based on a class of small molecules called halogenated xanthenes (HX). The company’s main molecule is RBS. A second HX molecule was synthesized.
Provectus’ drug discovery and development programs include investigational drugs and drug targets in oncology (clinical stage), dermatology (clinical stage), hematology, virology, microbiology, ophthalmology (clinical stage) and animal health , and use multiple routes of administration, such as intralesional (IL), topical (.top), oral (PO), inhaled (.inh), intranasal (IN), and intravenous (IV).
Information about the Company’s clinical trials can be found in the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information about Provectus, please visit the company’s website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of United States securities laws, relating to the business of Provectus and its affiliates, which are based on management’s opinions and estimates. of the Company and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast, ” “may,” “will,” “plan,” “predict,” “potential,” “targeting,” “intention,” “could,” “might,” “should,” “believe,” and similar words suggesting future results or forward-looking statements.
The safety and effectiveness of the agents and/or uses under investigation have not been established. There is no guarantee that agents will receive health authority approval or be commercially available in a country for the uses investigated or that these agents as products will achieve particular revenue levels.
Due to the risks, uncertainties and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result new information, future events or otherwise, except in accordance with applicable securities laws. Forward-looking statements are expressly qualified by this cautionary statement.
The risks, uncertainties and assumptions include those discussed in the company’s filings with the Securities and Exchange Commission (SEC), including those described in Section 1A of:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Phone: (866) 594-5999